S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   1384
 
                        2017-2018 Regular Sessions
 
                           I N  A S S E M B L Y
 
                             January 12, 2017
                                ___________
 
 Introduced  by  M. of A. ZEBROWSKI, CUSICK, ORTIZ, GALEF, COLTON, JENNE,
   BRINDISI, JAFFEE, TITUS, GUNTHER, COOK, TITONE,  MAGNARELLI,  BARRETT,
   STIRPE, BUCHWALD, LOPEZ, MOSLEY, HUNTER -- Multi-Sponsored by -- M. of
   A.  BARCLAY, CROUCH, DINOWITZ, FINCH, HAWLEY, MAGEE, McKEVITT, MONTES-
   ANO,  PALMESANO,  PEOPLES-STOKES, PERRY, RODRIGUEZ, STECK -- read once
   and referred to the Committee on Health
 
 AN ACT to amend the public health law, in relation to adding  cannabimi-
   metic agents to the schedule of controlled substances
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Schedule I of section 3306 of  the  public  health  law  is
 amended by adding a new subdivision (g) to read as follows:
   (G)  (1) CANNABIMIMETIC AGENTS. UNLESS SPECIFICALLY EXEMPTED OR UNLESS
 LISTED IN ANOTHER SCHEDULE, ANY MATERIAL, COMPOUND, MIXTURE, OR PREPARA-
 TION THAT IS NOT APPROVED BY THE FEDERAL FOOD  AND  DRUG  ADMINISTRATION
 (FDA)  WHICH  CONTAINS  ANY  QUANTITY OF CANNABIMIMETIC AGENTS, OR WHICH
 CONTAINS THEIR SALTS, ISOMERS, AND SALTS OF ISOMERS WHENEVER THE  EXIST-
 ENCE OF SUCH SALTS, ISOMERS, AND SALTS OF ISOMERS IS POSSIBLE WITHIN THE
 SPECIFIC CHEMICAL DESIGNATION.
   (2)  AS  USED  IN  THIS  SUBDIVISION, THE TERM "CANNABIMIMETIC AGENTS"
 MEANS ANY SUBSTANCE THAT IS A CANNABINOID RECEPTOR TYPE 1 (CB1 RECEPTOR)
 AGONIST AS DEMONSTRATED BY BINDING STUDIES AND FUNCTIONAL ASSAYS  WITHIN
 ANY OF THE FOLLOWING STRUCTURAL CLASSES:
   (I)  2-(3-HYDROXYCYCLOHEXYL)PHENOL WITH SUBSTITUTION AT THE 5-POSITION
 OF THE PHENOLIC RING BY ALKYL OR ALKENYL, WHETHER OR NOT SUBSTITUTED  ON
 THE CYCLOHEXYL RING TO ANY EXTENT.
   (II)  3-(1-NAPHTHOYL)INDOLE  OR 3-(1-NAPHTHYLMETHANE)INDOLE BY SUBSTI-
 TUTION AT THE NITROGEN ATOM OF THE INDOLE RING, WHETHER OR  NOT  FURTHER
 SUBSTITUTED ON THE INDOLE RING TO ANY EXTENT, WHETHER OR NOT SUBSTITUTED
 ON THE NAPHTHOYL OR NAPHTHYL RING TO ANY EXTENT.
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD04439-01-7
              

 A. 1384                             2
 
   (III)  3-(1-NAPHTHOYL)PYRROLE  BY SUBSTITUTION AT THE NITROGEN ATOM OF
 THE PYRROLE RING, WHETHER OR NOT FURTHER SUBSTITUTED IN THE PYRROLE RING
 TO ANY EXTENT, WHETHER OR NOT SUBSTITUTED ON THE NAPHTHOYL RING  TO  ANY
 EXTENT.
   (IV)  1-(1-NAPHTHYLMETHYLENE)INDENE  BY SUBSTITUTION OF THE 3-POSITION
 OF THE INDENE RING, WHETHER OR NOT FURTHER  SUBSTITUTED  IN  THE  INDENE
 RING  TO  ANY EXTENT, WHETHER OR NOT SUBSTITUTED ON THE NAPHTHYL RING TO
 ANY EXTENT.
   (V) 3-PHENYLACETYLINDOLE OR 3-BENZOYLINDOLE  BY  SUBSTITUTION  AT  THE
 NITROGEN  ATOM OF THE INDOLE RING, WHETHER OR NOT FURTHER SUBSTITUTED IN
 THE INDOLE RING TO ANY EXTENT, WHETHER OR NOT SUBSTITUTED ON THE  PHENYL
 RING TO ANY EXTENT.
   (3) SUCH TERM INCLUDES:
   (I)      5-(1,1-DIMETHYLHEPTYL)-2-{(1R,3S)-3-HYDROXYCYCLOHEXYL}-PHENOL
 (CP-47,497);
   (II)      5-(1,1-DIMETHYLOCTYL)-2-{(1R,3S)-3-HYDROXYCYCLOHEXYL}-PHENOL
 (CANNABICYCLOHEXANOL OR CP-47,497 C8-HOMOLOG);
   (III) 1-PENTYL-3-(1-NAPHTHOYL)INDOLE (JWH-018 AND AM678);
   (IV) 1-BUTYL-3-(1-NAPHTHOYL)INDOLE (JWH-073);
   (V) 1-HEXYL-3-(1-NAPHTHOYL)INDOLE (JWH-019);
   (VI) 1-{2-(4-MORPHOLINYL)ETHYL}-3-(1-NAPHTHOYL)INDOLE (JWH-200);
   (VII) 1-PENTYL-3-(2-METHOXYPHENYLACETYL)INDOLE (JWH-250);
   (VIII) 1-PENTYL-3-{1-(4-METHOXYNAPHTHOYL)}INDOLE (JWH-081);
   (IX) 1-PENTYL-3-(4-METHYL-1-NAPHTHOYL)INDOLE (JWH-122);
   (X) 1-PENTYL-3-(4-CHLORO-1-NAPHTHOYL)INDOLE (JWH-398);
   (XI) 1-(5-FLUOROPENTYL)-3-(1-NAPHTHOYL)INDOLE (AM2201);
   (XII) 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE (AM694);
   (XIII) 1-PENTYL-3-{(4-METHOXY)-BENZOYL}INDOLE (SR-19 AND RCS-4);
   (XIV)   1-CYCLOHEXYLETHYL-3-(2-METHOXYPHENYLACETYL)INDOLE  (SR-18  AND
 RCS-8); AND
   (XV) 1-PENTYL-3-(2-CHLOROPHENYLACETYL)INDOLE (JWH-203).
   § 2. This act shall take effect on the ninetieth day  after  it  shall
 have become a law.